— Early sign of Alzheimer's reversed in lab — One of the earliest known impairments caused by Alzheimer's disease - loss of sense of smell - can be restored by removing a plaque-forming protein in a mouse model of the disease,…
— Parental controls on embryonic development? — When a sperm fertilises an egg, each contributes a set of chromosomes to the resulting embryo, which at these very early stages is called a zygote. Early on, zygotic genes are inert,…
— Newly discovered heart stem cells make muscle and bone — Researchers have identified a new and relatively abundant pool of stem cells in the heart. The findings in the December issue of Cell Stem Cell, a Cell Press publication, show that…
— BUSM researchers develop blood test to detect membranous nephropathy — Research conducted by a pair of physicians at Boston University School of Medicine (BUSM) and Boston Medical Centre (BMC) has led to the development of a test that can help diagnose…
— New hip implants no better than traditional implants — New hip implants appear to have no advantage over traditional implants, suggests a review of the evidence published on bmj.com today…
— Action needed to improve men's health in Europe — Policies aimed specifically at men are urgently needed to improve the health of Europe's men, say experts on bmj.com today…
— Probiotics reduce infections for patients in intensive care — Traumatic brain injury is associated with a profound suppression of the patient's ability to fight infection. At the same time the patient also often suffers hyper-inflammation, due…
— High blood sugar levels in older women linked to colorectal cancer — Elevated blood sugar levels are associated with an increased risk of colorectal cancer, according to a study led by researchers at Albert Einstein College of Medicine of Yeshiva University.…
— Engineered botulism toxins could have broader role in medicine — The most poisonous substance on Earth - already used medically in small doses to treat certain nerve disorders and facial wrinkles - could be re-engineered for an expanded role in helping…
CSIRO ready to commercialise new GI technology
The CSIRO Food Futures Flagship has developed an automated instrument for accurately predicting glycaemic index (GI) and resistant starch (RS) in food products. The prototype device is an in vitro (bench top) robotic machine that acts as an 'artificial gut' to process large numbers of food samples for a fraction of the time and cost required by the standard in vivo (human) method.
The device has been validated as a rapid and reliable predictor of the GI and RS content of foods. Its principal purpose is to help food manufacturers develop a wider range of healthy food products far more cheaply and quickly than possible previously.
The CSIRO validation program for the instrument has involved the testing of a broad range of commercial foods with a wide spectrum of GI and RS values. The results have been benchmarked against 'gold standard' human-based tests on the same foods.
Dr David Topping, a chief research scientist with the CSIRO's Food Futures National Research Flagship, said the device is being commercialised to help address the growing global demand for foods with defined health benefits through low GI and higher RS content.
'This instrument will be a valuable tool for manufacturers as they develop new formulations and processes to make the products which consumers need,' Dr Topping said. 'The new device will make preliminary testing quicker, easier and more cost-effective, thus accelerating the path to market for these new foods.'
Associate Professor Jonathan Shaw, Associate Director of the Baker IDI Heart and Diabetes Institute in Melbourne, said the Institute's research team has been working with CSIRO to validate results obtained from the device.
'With the growing epidemic of obesity, diabetes and cardiovascular disease, both in Australia and around the world, there is increasing demand for low GI and high RS foods. Consumers really need greater access to products with appropriate health benefits, and we believe this new GI and RS predictor will help achieve that goal,' Professor Shaw said.
'The CSIRO's device looks promising in predicting GI and, once commercialised, it could play an important role in making a wider range of health-promoting foods available.'
CSIRO will release an international Expression of Interest (EOI) on 14 November 2008 seeking proposals from suitable companies to commercialise the new technology.
Or subscribe for our Newsletter, a free e-mail publication. It is published practically every day.
Patient-derived induced stem cells retain disease traits
How the brain thinks about crime and punishment
Loving the addict
Professor publishes 'Folktales of the Amazon'